Why PTC Therapeutics (PTCT) Stock Is Rallying Today
The bank believes that, in the wake of the results from the Phase 3 trial of PTCT's drug known as Sepiapterin, the product is viewed as likely to be approved by the FDA.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 6,378,000 | $287,902,920 | -12% | 3.92% |
| 2. | D E Shaw D. E. Shaw | 1,542,292 | $69,619,061 | +9% | 0.05% |
| 3. | Point72 Asset Management Steve Cohen | 1,443,362 | $65,153,361 | +151% | 0.14% |
| 4. | Driehaus Capital Richard Driehaus | 1,041,059 | $46,993,403 | 0.38% | |
| 5. | 35,984,000 | $40,124,947 | -13% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | 33,700 | 2023-12-12 | Filing | ||
| $32.48 | 10,000 | Director | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | Director | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | Director | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | Officer | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.50 | 1,662 | 64,321 | 2025-01-08 | Filing | ||
| $45.34 | 1,291 | 65,983 | 2025-01-07 | Filing | ||
| $44.50 | 2,136 | 86,805 | 2025-01-08 | Filing | ||
| $45.34 | 1,599 | 88,941 | 2025-01-07 | Filing | ||
| $44.50 | 2,402 | 283,830 | 2025-01-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,178,822 | $414,332,026 | 0% | |
| 2. | 7,898,801 | $356,551,878 | 0% | |
| 3. | 7,393,127 | $333,725,753 | 5.04% | |
| 4. | 4,787,123 | $216,090,731 | 0.03% | |
| 5. | 3,286,729 | $148,362,947 | 0.26% |
News See All
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript
Operator: Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to PTC Second Quarter 2024 Financial Results Conference Call.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.29.
Analysts on Wall Street Lower Ratings for These 5 Stocks
On December 19, Morgan Stanley analyst Jeffrey Hung downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) from Equalweight to Underweight, within the biotechnology industry.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
PTC Therapeutics (PTCT) Lost 16% in Q2
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here.
Analysts on Wall Street Lower Ratings for These 5 Stocks
Federal Realty Investment Trust (NYSE:FRT) is a leading real estate company specializing in high-quality retail properties in major coastal markets from Washington, D.C., to Boston, San Francisco, and...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by and welcome to the PTC Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
